AUGUST 22, 1999 (1:00-5:30PM)

Session I: CAM and Chronic Liver Diseases: Introduction and Definitions

Chair: Leonard Seeff, MD

1:00-1:15	Welcome and Introduction	Leonard Seeff, MD NIDDK, NIH
1:15-1:35	Overview of Center for Complementary & Alternative Medicine (CAM)	Richard Nahin, MPH, PhD NCCAM, NIH
1:35-1:55	Spectrum of Botanicals and Herbal Supplements	Edward Croom, PhD University of Mississippi
1:55-2:15	Epidemiology of CAM in Clinical Practice	David Eisenberg, MD Beth Israel Deaconess Medical Center, Harvard Medical School, Boston
2:15-2:45	Discussion
2:45-3:00	Break
3:00-3:20	Spectrum of Liver Disease and Treatment Strategies (Hepatocellular & Cholestatic)	Karen Lindsay, MD USC
3:20-3:40	Use of CAM by Patients in Liver Diseases Clinics	Doris Strader, MD VAMC Washington
3:40-4:00	CAM and Chronic Liver Disease: View of the Practitioner	Andrew L. Rubman, ND University of Bridgeport, Southbury Clinic
4:00-4:20	Regulation of CAM: Role of the FDA	Freddie Ann Hoffman, MD FDA
4:20-5:00	Discussion

AUGUST 22, 1999 (6:30-9:30 PM ), Marriott Hotel, 5151 Pooks Hill Rd., Bethesda, MD

Complimentary and Alternative Medicine in Liver Diseases: Meet the Experts Forum

A forum for individuals to meet and question experts in the field of alternative medicine regarding informed choices for treatment strategies, co-sponsored by the American Liver Foundation and Hepatitis International Foundation

Panel	Expertise
David Eisenberg, MD, Beth Israel Deaconess Hospital	Epidemiology of CAM
Andrew L. Rubman, ND, Southbury Clinic	Naturopathic Medicine
Freddie Ann Hoffman, MD, FDA	Federal Regulatory Issues
Bruce Bacon, MD, St. Louis University	Liver Disease
Anna MacIntosh, PhD, ND, Nat'l. Coll. Naturopathic Med	Naturopathic Medicine
Thomas Schiano, MD, Albert Einstein College of Medicine	Liver Toxicity
Moderator: Jay Hoofnagle, MD, NIDDK, NIH	Liver Disease

Agenda
6:30-6:40- Welcome, Introductions	Jay Hoofnagle, MD
6:40-6:50- Opening Statement, ALF	Alan P. Brownstein, MPH
6:50-7:00- Opening Statement, HFI	Thelma King Thiel
7:00-8:00- HFI sponsored Guests
8:00-8:15- break
8:15-9:15 ALF sponsored Guests
9:15-9:30- Summary and Conclusions	Jay Hoofnagle, MD

Monday, August 23, 1999

Session 2: Design of Outcome Research

Chair: Bruce Bacon, MD

8:30-8:50	Methods and Statistical Considerations in Designing Controlled Clinical Trials for Therapy	Elizabeth Wright, PhD New England Research Institute, Boston
8:50-9:10	Lessons From Controlled Clinical Trials in CAM Implications for the Study of Liver Diseases	Wayne Jonas, MD USUHS
9:10-9:30	Special Consideration in Alternative Medicine Clinical Trials and the Placebo Effect	Ted Kaptchuk, OMD Beth Israel Hospital, Boston
9:30-9:50	Clinical Trial Outcome Measures for Hepatitis	Anna MacIntosh, PhD, ND National College of Naturopathic Medicine
9:50-10:15	Discussion
10:15-10:45	Break

Session 3: Liver Disease and CAM

Chair: Jay Hoofnagle, MD

10:45-11:15	Silymarin (Milk Thistle) and Liver Disease	Peter Ferenci, MD Department of GI/Hepatology University of Vienna
11:15-11:35	Therapeutic Evaluation of Hepatitis Remedies: The Usefulness of Ethnomedical Focusing Techniques	Memory Elvin-Lewis Washington University
11:35-12:00	Discussion
12:00-1:00	Lunch and Posters (Lunch Provided)
1:00-1:20	Herbal Medicine 861 has Direct Antiproliferative Effects on Hepatic Stellate Cells	Bruce Bacon, MD St. Louis University
1:20-1:40	Glycyrrhizin	Mark Zern, MD Thomas Jefferson Hospital
1:40-2:00	Long Term Effect of Sho-saiko-to (TJ-9) on the Levels of markers for Hepatic Fibrinogenesis In Chronic Hepatitis C	Hiromasa Ishii, MD Keio University, Japan
2:00-2:20	Immune modulation, CAM and Liver Disease	Craig McClain, MD University of Kentucky
2:20-2:40	Discussion
2:40-3:00	Break

Session 4: Spectrum of Botanicals for Use in Liver Diseases

Chair: Freddie Ann Hoffman, MD

3:00-3:20	Botanicals and Formulations: Practical Solutions	Ed Alstat RPh, ND Eclectic Institute, Inc.
3:20-3:40	IND's for Botanicals and Formulations	Floyd Leaders, PhD Bethesda
3:40-4:00	US Pharmacopeia and CAM	Srini Srinivasan, PhD Dietary Supplement Division
4:00-4:30	Discussion
4:30	Posters and Reception

August 24, 1999

Session 5: Cultural-Based Use of Botanicals in Liver Disease

Chair: John C. Chah, PhD

8:30-8:50	Experimental and Clinical Study on Inhibition and Reversion of Liver Fibrosis with Integrated Chinese And Western Medicine	Baoen Wang, MD Beijing Friendship Hospital Capital University of Medical Sciences
8:50-9:10	Clinical and Pharmacological Studies on Liver Diseases by Kampo Herbal Medicine in Japan	Jong-Chol Cyong, PhD Graduate School of Medicine University of Tokyo
9:10-9:30	Antiviral Activity of Aucubin Derived from Traditional Chinese Herbs in HepG2, Woodchucks And Humans Infected with HBV	Il Moo Chang, PhD National Products Research Institute Seoul National University
9:30-9:50	New Evidence for the Rationale of Systemic Therapy with Proteolytic Enzymes and L-Ornitin Aspartate In Liver Disease	Ralf Kleef, MD German Medical Boards for Complementary Medicine
9:50-10:10	Recent Advances in Liver Diseases in Ayuvedic Medicine	Shri K. Mishra, MD, PhD University of Southern California School of Medicine
10:10-10:30	Dietary Botanical Supplements with Antiviral and Antiinflammatory Properties Used in the Treatment of Liver Disorders In Traditional African Medicine	Dr. Maurice Iwu, PhD Bioresources Development and Conservation Programme, Nigeria
10:30-10:45	Discussion
10:45-11:20	Break & Snack

Session 6: Adverse Effects, Hepatotoxicity, and Quality Control

Chair: Jim Lewis, PhD

11:20-11:40	Toxicity of Herbal Products, Excluding Liver Toxicity, by Organ System	Mary Palmer, MD
11:40-12:00	Hepatotoxicity of Herbs and Other Botanicals	Thomas Schiano,MD Mount Sinai
12:00-12:20	Reporting of Adverse Effects: The FDA Perspective	Lori Love, MD PhD FDA
12:20-12:40	Adverse Effects of Botanicals: The CDC Experience	Rossanne Philen, MD, MS CDC
12:40-1:00	Quality Control and Quality Assurance of Botanicals	Yuan-yuan Chiu, PhD FDA
1:00-1:30	Discussion
1:30-1:45	Summary	Jay Hoofnagle, MD NIDDK

Back to News Advisory